Skip to main content

ESMO

News
05/26/2020
A cost-benefit analysis published in The Lancet Oncology (May 2020;21[5]:664-670) compared the prices and clinical benefit of cancer drugs in the US vs Europe. Both the US and European countries are faced with the...
A cost-benefit analysis published in The Lancet Oncology (May 2020;21[5]:664-670) compared the prices and clinical benefit of cancer drugs in the US vs Europe. Both the US and European countries are faced with the...
A...
05/26/2020
Journal of Clinical Pathways
Research in Review
12/13/2016
JCP Editors
Fewer than one-third of randomized controlled trials reporting statistically significant outcomes for novel systemic therapies in solid cancers met the European Society of Medical Oncology’s (ESMO) threshold for...
Fewer than one-third of randomized controlled trials reporting statistically significant outcomes for novel systemic therapies in solid cancers met the European Society of Medical Oncology’s (ESMO) threshold for...
Fewer...
12/13/2016
Journal of Clinical Pathways
11/30/2016
JCP Editors
Current value frameworks issued by leading medical societies may not be easily generalizable to the treatment of hematologic malignancies, according to two studies presented at the 2016 ASH Annual Meeting and...
Current value frameworks issued by leading medical societies may not be easily generalizable to the treatment of hematologic malignancies, according to two studies presented at the 2016 ASH Annual Meeting and...
...
11/30/2016
Journal of Clinical Pathways